Compared with placebo, the fusion protein sotatercept improved exercise capacity in patients with pulmonary arterial hypertension who were receiving stable background therapy, the STELLAR trial
In Taiwan, an analysis of a national insurance claims database shows potential differences in severe acute exacerbation (AEs) among fixed-dose combinations (FDCs) of long-acting muscarinic
In a phase 2b trial of 5,782 older adults, an adenovirus serotype 26 respiratory syncytial virus (RSV) vector encoding a prefusion F (preF) protein (Ad26.RSV.preF) protein
In an international, phase 3 trial of 24,966 older adults, a single dose of an AS01E-adjuvanted respiratory syncytial virus (RSV) prefusion F protein–based candidate vaccine (RSVPreF3
The CAPTURE tool was ineffective in identifying undiagnosed, clinically important COPD in the primary care setting, researchers report. The tool “had a low sensitivity but
Among individuals with smoking exposure with and without COPD, a study identifies “risk factors for suicide/overdose … that emphasize the subjective experience of illness over
A meta-analysis of 60 randomized controlled trials examines all-cause mortality In 103,034 patients with COPD who were using inhaled therapy with or without inhaled corticosteroids
FDA last week approved ublituximab-xiiy (Briumvi, TG Therapeutics) for treating adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease,
Results of a clinical trial do not support the use of daily low-dose, extended-release morphine to relieve severe chronic breathlessness in people with COPD. The
Short courses of antibiotic therapy are noninferior to longer regimens in infants and young children aged 2 to 59 months with nonsevere community-acquired pneumonia (CAP),